Economics of treating chronic subclinical streptococcus uberis cases by Hogeveen, H. et al.
ECONOMICS OF TREATING CHRONIC SUBCLINICAL 
STREPTOCOCCUS UBERIS CASES 
Henk Hogeveen ' , Jantijn M. Swinkels , Wilma Steeneveld , 
Jolanda G.A.Rooijendijk2 and Ruth N. Zadoks4 
'Utrecht University, Utrecht, the Netherlands 
2Wageningen University, Wageningen, the Netherlands 
3Herd Health Consultant, Noordbeemster, The Netherlands 
4Cornell University, Ithaca, New York 
Mastitis is generally regarded as the most costly disease in dairy cattle in developed countries 
Costs are mainly due to milk production losses, culling, treatment and discarded milk due to 
antibiotic residues. Additional costs include decreased fertility, changed composition of milk and 
risk of violation of bulk tank limits or loss of premium for low bulk milk somatic cell count. In 
cases of clinical mastitis, farmers are usually willing to treat animals because the animals are 
diseased, milk is visibly abnormal, and/or milk production has decreased dramatically. In cases 
of subclinical mastitis, animals are not clinically diseased and milk is not visibly abnormal. 
Therefore, inflammation is not recognizable without additional testing and treatment may not 
seem necessary. Treatment of subclinical mastitis is often deferred until the dry period. However, 
subclinical mastitis, like clinical mastitis, affects milk quality and quantity, and is associated with 
economic losses as described above. Furthermore, cows with subclinical infections may act as a 
source of infection for other animals, resulting in spread of a mastitis problem in the herd. 
However, treatment of subclinical Streptococcus agalactiae infections during lactation is 
economically profitable (Yamagata et al. 1987). The success of treatment programs for S. 
agalactiae is partly due to the high proportion of quarters cured after treatment, and to the 
prevention of disease transmission that is achieved through cure of infected animals. Reported 
cure proportions for Streptococcus uberis are high too, ranging from 50% to 100% (Bramley, 
1984; Owens et al. 1997; McDougall, 1998). Recent studies have shown that treatment of 
subclinical infections with non-agalactiae streptococci may contribute to prevention of clinical 
mastitis (St. Rose et al. 2003) and to prevention of streptococcal transmission (Zadoks et al. 
2001, 2003). The cost-benefit ratio of antibiotic treatment of subclinical S. uberis infections 
during lactation has not been determined. 
The purpose of this paper is to explore the economic benefit of antibiotic treatment of chronic 
subclinical 5. uberis infections during lactation, including'the indirect effects of treatment, 
prevention of clinical mastitis and prevention of transmission. 
A Deterministic Simulation Model 
Partial budgeting was used for the development of a deterministic simulation model to estimate 
the net cost or benefit of lactational treatment of subclinical 5. uberis mastitis with antibiotics. 
Input variables for the model were based on literature, if available, and the 2003/2004 dairy 
situation and prices in the Netherlands. The model works at cow level with a time horizon of one 
lactation. A schematic outline of the deterministic model is depicted in Figure 1. 
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Figure 1. The deterministic model for effect of antibiotic treatment versus no treatment 
of chronic subclinical intramammary infections with S. uberis. 
The starting point for decisions on lactation treatment is the moment of detection of a chronic 
case of subclinical mastitis, which is after a minimum of two consecutive test days with an 
increased SCC. Bacteriological examination has taken place to confirm an infection with S. 
uberis. Antibiotic treatment can lead to cure or no cure. The consequences of the latter are the 
same (also in probabilities) as giving no treatment. When not treated or not cured after treatment, 
a cow may cure spontaneously, my get a so-called clinical flare-up or may maintain subclinical. 
When a cow is not cured (due to treatment or spontaneously), she is infectious and thus may 
infect other cows, depending on the transmission rate (R) of that specific strain of S. uberis and 
herd management (Zadoks et al., 2001). A newly infected cow may cure spontaneously, become 
clinical or become a chronic subclinical mastitis case. 
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The following parameters are used in the model (including assumptions and used references for 
the default value of the parameter). The basic treatment is a short, 3-day treatment with 
intramammary or parenteral antibiotics. The probability of cure after treatment is 60 % 
(McDougall, 1998; St. Rose et al. 2003; DeLuyker et al. 2001). The probability of spontaneous 
cure is 20 % (St. Rose et al. 2003; DeLuyker et al. 2001). The probability of clinical flare-ups is 
estimated at 20 % (Lam, 1996; Zadoks et al. 2003). Given the probability of spontaneous cure 
and clinical flare-ups, the probability of remaining subclinical is 60 %. The probability that a 
cow with a persistent subclinical mastitis is infecting other cows is represented by the 
reproduction ratio (R). This parameter represents the total number of new infections that is 
caused by an infected animal and is based upon the infectiousness of 5. uberis (transmission 
parameter ß) and the duration of the infection (t). In a field study, ß was found to be 0.033 
during an epidemic outbreak of S. uberis mastitis, while it was much lower, 0.005, during a non-
outbreak situation (Zadoks et al. 2001). The duration of a non-cured S. uberis infection, after 
detection, is estimated to be 30 days on average. For the purpose of this study, treatment of 
chronic S. uberis infections, R is estimated to be between 0 and 1. As default value R = 0.15 is 
used. When transmission of infection occurs, the new infection can be clinical or subclinical. For 
5. uberis, the probability that a new infection is clinical is estimated to be 30 % (Lam, 1996; 
Zadoks et al. 2003; Jayarao et al. 1999), 40 % is assumed to cure within a few weeks and 30 % is 
assumed to become chronic subclinical mastitis cases. 
Economic effects of treatment of chronic subclinical mastitis caused by S. uberis are calculated 
by means of partial budgeting. A partial budget can be used to estimate the change that will 
occur in farm profit from some change in the management, by considering only those items of 
returns and costs that change. The format of a partial budget is made up of four sections: 
additional returns, reduced costs, returns forgone and extra costs (Dijkhuizen and Morris, 1997). 
In this study, the basic situation is a chronic subclinical 5. uberis infection which is not treated. 
The change in management is treatment of this infection. The additional returns are a possible 
increase of milk production when the subclinical mastitis case is cured. Reduced costs consist of 
a reduced probability of clinical mastitis, a reduction of costs associated with persistent 
subclinical mastitis and a reduction of mastitis (either clinical or subclinical) in other cows due to 
infectiousness of the current mastitis case. Moreover, reduced costs consist of a reduction in 
culled animals (calculated by the retention pay-off), reduced number of penalties for increased 
bulk milk SCC and reduced costs of decreased fertility (the latter two are expected to be minimal 
for the Dutch circumstances). Returns forgone consist of discarded milk because of the 
withdrawal period of milk after antibiotic treatment. Extra costs consist of the antibiotics and 
labor necessary to carry out the treatment. In Table 1, the input values to calculate the partial 
budget are given. The assumptions behind these input variables can be found in Swinkels et al., 
2005. 
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Table 1. Input parameters used in the partial budget to estimate the costs and benefits of treatment 
of chronic subclinical S. uberis mastitis. Basic situation is no treatment. Cost estimates are given 
in Euro (in December 2004 € 1.- « $ US 1.25) 
Parameter Value 
Treatment and cure 
Duration treatment (days) 3 
Costs antibiotics (€) 27 
Withdrawal period (after end of treatment; days) 3 
Cost of labor (€/hour) 01 
Milk production 
Milk production at treatment (kg/day) 25 
Cost of discarded milk (€/kg)2 0.143 
Increase of production after cure (kg/lactation) 0 
Production decrease of spontaneously cured new mastitis case (kg/lactation) 72 
Production decrease of new chronic subclinical mastitis case (kg/lactation) 300 
Cost of decreased milk production (€/kg)2 0.074 
Mastitis 
Cost of new case of clinical mastitis (€) 2095 
Cost of clinical flare-up (€) 1635 
Culling 
Probability of culling 12% 
Retention pay-off (€) 5066 
Other factors 
Reduced fertility due to mastitis 0 
Probability milk payment penalty BMSCC when cow is not cured 0 
Milk payment penalties due to increased bulk milk SCC (€) 335 
Probability milk payment penalty antibiotics 0 
Milk payment penalties due to antibiotic residues in milk (€) 385 
On a family farm there is no alternative use of labor. Therefore, the economic value of labor is 
regarded to be € 0.-
2Under a situation with milk quota and no alternative use for farm labor and barn 
3
«€0.53/US Gallon 
4
«€0.26/US Gallon 
5Based on de Vos and Dijkhuizen (1998). A large component of the cost for clinical mastitis is 
made up by milk production losses (€ 92.-). In the case of clinical flare-up, a large part of the 
milk production losses already occurred during the subclinical phase. Therefore, the damage for 
milk production losses has been adjusted in case of a clinical flare-up. 
6The retention pay-off differs from cow to cow (Dijkhuizen and Morris 1998). In this case an 
average cow in parity 2, 7 months in lactation and 2 months pregnant under Dutch 2004 market 
situation is taken. 
Sensitivity Analysis 
Sensitivity analysis is used to calculate what happens to the net result if one input variable at a 
time is changed from the average situation. Four groups of input variables have been adjusted: 
cure rates and clinical flare-ups, infectiousness of persistent subclinical cases, production effects 
and economic parameters. When estimates for input variables that have a strong impact on 
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economic outcome are scarce or vary widely among sources, further research into the value of 
that parameter may be indicated. 
Besides a sensitivity analysis, where variables are adjusted one at each run, an economic model 
can also be used to carry out scenario studies. In a scenario study, multiple variables are changed 
at the same time, representing a possible scenario. In this study only one scenario has been 
calculated: a longer treatment as proposed by DeLuyker et al. (2001). In this scenario, due to a 
longer treatment (8 days instead of 3 days), the cure rate will increase to 90 %. On the other hand 
the costs for treatment and milk withdrawal will also increase. 
Results 
Under the basic situation described in this paper, the average economic benefit of treatment of 
chronic subclinical infection with S. uberis is given in Table 2. The costs and benefits are almost 
equal around € 48, and the net result of treatment is € 0.55. The most important beneficial factors 
of treatment are less culling (45 %) and a reduced risk of clinical mastitis (40 %). Under the 
basic circumstances the prevention of new infections denotes 15 % of the benefits. Costs are due 
to withheld milk and, of course, the used antibiotics. 
Table 2. Costs and benefits (€; in December 2004 € 1.- « $ US 1.25) of antibiotic treatment of 
chronic subclinical S. uberis mastitis under the basic assumptions. 
Benefits 
Extra revenues 
Milk production increase 
Reduced costs 
Reduced clinical mastitis 
Less new infections 
Less culling 
Less BMSCC penalties 
Total 
0 
19.56 
7.13 
21.86 
0 
48.55 
Net result: 
Costs 
Reduced revenues 
Withheld milk 
Extra costs 
Antibiotics 
Labor 
More penalties due to antibiotics 
Total 
0.55 
21 
27 
0 
0 
48 
Results of sensitivity analysis are shown in Table 3. The most important parameters to determine 
the effect of treatment of chronic subclinical S. uberis are: cure rate after treatment, the 
infectiousness (a) of the pathogen involved (to a lesser extend the infectious period), risk of a 
penalty for a high BMSCC, costs of antibiotics, value of a decreased milk production (and thus 
also the value of discarded milk) and the risk and cost of culling. Parameters such as spontaneous 
cure, production changes and costs of clinical mastitis had less effect. 
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Table 3. Results (€; in December 2004 € 1.- « $US 1.25) of the sensitivity analysis for treatment 
of chronic subclinical S. uberis mastitis. 
Factor 
Basic 
Cure rates and clinical flare-ups 
Cure after treatment 50 % 
Cure after treatment 70 % 
Spontaneous cure 10 % 
Spontaneous cure 30 % 
Spontaneous cure after treatment 10 % 
Spontaneous cure after treatment 30 % 
Clinical flare-ups 10 % 
Clinical flare-ups 30 % 
Infectiousness 
Duration of infection (t) 20 days 
Duration of infection (t) 40 days 
Duration of infection (t) 60 days 
Infectiousness of pathogen (a) 0 
Infectiousness of pathogen (a) 0.0025 
Infectiousness of pathogen (a) 0.015 
Infectiousness of pathogen (a) 0.033 
Production effects 
Recovery of milk production after cure 25 % 
Recovery of milk production after cure 50 % 
Production decrease subclin. mastitis 200 kg 
Production decrease subclin. mastitis 400 kg 
Risk of culling 6% 
Risk of culling 18% 
Risk of penalty due to high BMSCC 5 % 
Risk of penalty due to high BMSCC 10 % 
Economic factors 
Costs antibiotics € 17 
Costs antibiotics € 37 
Value milk production decrease middle 
Value milk prod, decrease high (no quotum) 
Costs clinical mastitis € 168 
Costs clinical mastitis € 250 
Retention pay-off € 250 
Retention pay-off € 750 
Original value 
60% 
60% 
20% 
20% 
20% 
20% 
20% 
20% 
30 days 
30 days 
30 days 
0.005 
0.005 
0.005 
0.005 
0% 
0% 
300 kg 
300 kg 
12% 
12% 
0% 
0% 
€27 
€27 
Low 
Low 
€206 
€206 
€506 
€506 
Costs 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
48 
38 
58 
58.5 
72 
48 
48 
48 
48 
Benefits 
48.55 
40.46 
56.64 
53.08 
44.01 
45.53 
51.57 
42.06 
55.04 
46.17 
50.92 
55.68 
41.42 
44.98 
62.81 
" 88.47 
51.07 
53.59 
48.4 
48.7 
36.96 
60.13 
54.58 
60.61 
48.55 
48.55 
49.15 
49.92 
42.57 
54.53 
37.24 
59.72 
Net result 
0.55 
-7.54 
8.64 
5.08 
-3.99 
-2.47 
3.57 
-5.94 
7.04 
-1.83 
2.92 
7.68 
-6.58 
-3.02 
14.81 
40.47 
3.07 
5.59 
0.40 
0.70 
-11.04 
12.13 
6.58 
12.61 
10.55 
-9.45 
-9.35 
-22.08 
-5.43 
6.53 
-10.76 
11.72 
The scenario with a longer treatment gave a net result of - € 41.53. The benefits of a higher cure 
rate were less than the increased costs due to more expenses on antibiotics and a large amount of 
discarded milk. 
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Discussion 
In Europe, where acceptable maximum levels for bulk milk somatic cell count are much lower 
than in the USA (400.000 cells/ml vs. 750.000 cells/ml, respectively) and where milk quotas are 
in place in many countries, antibiotics for treatment of subclinical mastitis during lactation are 
currently being marketed. The availability of these products, combined with results from recent 
research prompted us to re-examine the long-held position that lactational treatment of 
subclinical mastitis caused by non-agalactiae streptococci is not economically justified (Wilson 
et al. 1999). Results of this study show that, for an average situation, the benefits of treatment of 
chronic subclinical S. uberis mastitis equal the costs. In a comparable study where the same 
techniques have been applied on treatment of chronic subclinical mastitis caused by 5. uberis or 
5. dysgalactiae, the benefits were higher (net result € 11.62) (Swinkels et al., 2005). There were 
some differences in assumptions but an important difference was the spontaneous cure rate. 
Swinkels and co-workers averaged estimates for S. uberis and S. dysgalactiae, where S. 
dysgalactiae has a higher spontaneous cure rate than S. uberis. 
Factors that we took into account and that have not been considered in previous economic 
calculations include the prevention of clinical flare-ups of subclinical infections (St. Rose et al. 
2003) and the prevention of contagious transmission. Although S. uberis infections often have an 
environmental source (Phuektes et al. 2001; Wang et al. 1999; Zadoks et al., 2003), they may also 
spread from cow to cow (Phuektes et al. 2001; Zadoks et al. 2003). 
There is uncertainty about and variability in many input parameters in our model. Sensitivity 
analysis indicated that the most important factors affecting the outcome of our economic analysis 
could be associated with the biology of mastitis and its causative agents, herd management, and 
economic factors such as retention pay-off or cost of antibiotics. Some of these factors, e.g. the 
probability of cure, may be strain-dependent or cow-dependent. For example, for S. aureus it has 
been shown that some strains are more likely to cure than others (Sol et al. 2000), and also that 
some cows are more likely to cure than others, be it with (Sol et al. 1997, 2000) or without 
treatment (Schukken et al. 1999). These types of factors have not been determined for 5. uberis. 
Because bacterial flora, cow characteristics and management differ widely between farms, the 
economic outcome of lactational treatment of chronic subclinical streptococcal mastitis may be 
highly farm-dependent. 
In this study, we assumed the costs of penalties due to antibiotic residues in the milk, costs of 
other diseases resulting from mastitis and impact on fertility to be zero. All these costs can be 
substantial on specific farms, but were considered to be of minor importance on an average farm 
and for the average cow. Moreover, these costs are very difficult to quantify in a relatively 
simple model such as described in this paper. 
Partial budgeting is a relatively simple method to assess economic profitability of the treatment 
of mastitis. It is particularly useful for relative small changes on a farm, such as treatment vs. no 
treatment of animals. However, as for any simple model, model assumptions are relatively coarse 
when compared to the complexity of reality. To address simplifications and assumptions like the 
ones used in our model and our sensitivity analysis, and to obtain more accurate estimates of the 
range of economic effects and the probability of specific outcomes within that range, a stochastic 
model would need to be developed to assess the profitability of treatment of subclinical mastitis 
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caused by S. uberis. Such a model is currently under development and factors which are getting 
specific interest in this study are: moment of decision (days in lactation), uncertainty about the 
infectiousness of the causative pathogen and production characteristics of the treated cow. 
In conclusion, depending on circumstances such as prevailing bacterial flora, farm management 
and economic conditions, lactational treatment of chronic subclinical mastitis caused by S. 
dysgalactiae or S. uberis with antibiotics may or may not be economically beneficial. 
Identification of cow factors and bacterial strain characteristics associated with cure and/or 
transmission would improve the cow- and herd specific estimates of the economic outcome of 
antibiotic treatment. Stochastic modelling will be needed to perform more accurate calculations 
of the range and probabilities of potential economic outcomes of lactational treatment of chronic 
subclinical S. uberis mastitis. 
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